- BioNTech ( NASDAQ: BNTX ) has completed the building of its first plasmid DNA manufacturing facility in Marburg, Germany.
- Plasmid DNA are the building blocks for the manufacturing of mRNA-based vaccines and therapies, as well as cell therapies.
- The new plant will be used in support of product candidates and commercial products in cancer and infectious diseases.
- The facility actually covers two areas: clinical and commercial plasmid DNA. The clinical side is already running, while the commercial one should be operational by the end of the year .
- See why Seeking Alpha contributor Terry Chrisomalis recently called BioNTech ( BNTX ) a strong buy.
For further details see:
BioNTech finishes construction of first plasmid DNA manufacturing facility